InSilicoMinds was already in the room enabling and helping build and adopt the AI regulatory infrastructure and In Silico first approaches to support the pharmaceutical industry in Uzbekistan.
Last month our CEO Mr. Nirnith Devireddy and CSO Dr. Pranav Karmwar were invited to Tashkent by the Medical and Pharmaceutical Industry Development Agency, Ministry of Health, Republic of Uzbekistan and UZPharmAgency, where we worked closely with visionary First Deputy Minister of Health Abdulla Azizov and his leadership team.
Across two days of discussions and special workshops conducted by InSilicoMinds, we explored how AI, Modeling & Simulation, and in silico approaches can transform regulatory science and pharmaceutical development. 🤝
The timing is remarkable. As India and Uzbekistan partner to enable a Eurasian Pharmaceutical Corridor, Uzbekistan is rapidly emerging as a regional pharmaceutical and nutraceutical hub, driven by bold industrial policy:
- Dedicated pharma parks and manufacturing clusters attracting global investment
- Regulatory modernization aligned with international standards
- Strategic positioning between India, Russia, and Central Asia
- Trade-focused reforms designed to accelerate partnerships and exports
As the India-Uzbekistan pharmaceutical corridor strengthens, AI-enabled regulatory infrastructure and in silico approaches will be critical to scaling innovation and cross-border drug development.
We’re excited to work alongside visionary leaders helping shape the next era of AI-enabled drug development and regulatory science acceleration.
And this is only the beginning.
